518 Discovery of MACO-355, a novel, first in mechanism ligand-blocking independent anti-LILRB1/2 monoclonal antibody for cancer therapy

• Luca Cassetta,
• Carola Ries,
• Krzysztof B Wicher,
• Moritz Haneklaus,
• Alicia Poindron,
• Martha Lopez-Yrigoyen,
• Carmen Rodriguez Seoane,
• Maikel Fransen,
• Chantell Payton,
• Stephane Guillame,
• Stephen Myatt

Affiliations

Luca Cassetta

MRC Centre for Reproductive Health, The University of Edinburgh The Queen`s Medical Research Institute, Edinburgh, Edinburgh, UK

Carola Ries

Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

Krzysztof B Wicher

1Macomics, Cambridge, UK

Moritz Haneklaus

1Macomics, Cambridge, UK

Alicia Poindron

1Macomics, Cambridge, UK

Martha Lopez-Yrigoyen

2Macomics, Edinburgh, UK

Carmen Rodriguez Seoane

2Macomics, Edinburgh, UK

Maikel Fransen

1Macomics, Cambridge, UK

Chantell Payton

1Macomics, Cambridge, UK

Stephane Guillame

1Macomics, Cambridge, UK

Stephen Myatt

1Macomics, Cambridge, UK